Robust: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, MD1; Annalisa Chiappella, MD2; Randy D. Gascoyne, MD3; David W. Scott, MBChB, PhD1; Qingyuan Zhang, MD4; Wojciech Jurczak, MD, PhD5; MuHit Ozcan, MD, PhD5; Xiaonan Hong, MD1; Jun Zhu, MD6; Jie Jin, MD7; David Belada, MD10; Juan Miguel Bergua, MD11; Francesco Piazza, MD12; Heidi Mocikova, MD13; Anna Lia Molinari, MD14; Dok Hyun Yoon, MD15; Federica Cavallo, MD16; Monica Tani, MD17; Kazuhiro Yamamoto, MD, PhD18; Koji Kato, MD19; Myron Czuczman, MD21; Sarah Hersey, MS, MBA, RAC22; Adrian Kilcoyne, MD21; Jacqueline Russo, BS23; Krista Hudak, PharmD21; Jingshan Zhang, PhD21; Steve Wade, BS24; Thomas E. Witzig, MD1; and Umberto Vitolo, MD2; on behalf of the ROBUST Trial Investigators

 PURPOSE
Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding the immunomodulatory agent lenalidomide to R-CHOP improved outcomes in ABC-type DLBCL. The goal of the global, phase III ROBUST study was to compare lenalidomide plus R-CHOP (R2-CHOP) with placebo/R-CHOP in previously untreated, ABC-type DLBCL.

METHODS
Histology and cell-of-origin type were prospectively analyzed by central pathology prior to random assignment and study treatment. Patients with ABC-DLBCL received lenalidomide oral 15 mg/d, days 1-14/21 plus standard R-CHOP21 versus placebo/R-CHOP21 for six cycles. The primary end point was progression-free survival (PFS) per independent central radiology review.

RESULTS
A total of 570 patients with ABC-DLBCL (n = 285 per arm) were stratified by International Prognostic Index score, age, and bulky disease, and randomly assigned to R2-CHOP or placebo/R-CHOP. Baseline demographics were similar between arms. Most patients completed six cycles of treatment: 74% R2-CHOP and 84% placebo/R-CHOP. The most common grade 3/4 adverse events for R2-CHOP versus placebo/R-CHOP were neutropenia (60% v 48%), anemia (22% v 14%), thrombocytopenia (17% v 11%), and leukopenia (14% v 15%). The primary end point of PFS was not met, with a hazard ratio of 0.85 (95% CI, 0.63 to 1.14) and P = .29; median PFS has not been reached for either arm. PFS trends favoring R2-CHOP over placebo/R-CHOP were seen in patients with higher-risk disease.

CONCLUSION
ROBUST is the first DLBCL phase III study to integrate biomarker-driven identification of eligible ABC patients. Although the ROBUST trial did not meet the primary end point of PFS in all patients, the safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.

J Clin Oncol 39:1317-1328. © 2021 by American Society of Clinical Oncology

INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) comprises one-third of patients with mature B-cell non-Hodgkin lymphoma as the most common type of aggressive lymphoma.1,2 Standard first-line therapy for advanced-stage DLBCL currently relies on the anti-CD20 antibody rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).3,4 Although > 50% of patients experience long-term disease control with R-CHOP, approximately 30% in remission ultimately relapse at increasing rates, upon which outcomes are poor.5,6 Numerous trials attempted to improve outcomes by investigating alternate regimens, adding combination agents,7,8 and exchanging rituximab for type II anti-CD20 antibody obinutuzumab9; to date, none have demonstrated a clinically significant improvement.

DLBCL is a heterogeneous disease with two major biologically distinct pathophysiologic entities based on cell-of-origin (COO) and classified as germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes by gene expression profiling (GEP).10,11 These were discovered by GEP,11,12 then later translated into an immunohistochemistry (IHC) algorithm
CONTEXT

Key Objective
What is the potential improvement in outcomes with the combination of lenalidomide plus rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) over standard R-CHOP in previously untreated patients with diffuse large B-cell lymphoma who had activated B-cell-like disease (typically associated with worse prognosis)?

Knowledge Generated
The global, phase III ROBUST study did not meet the primary end point for significantly improved progression-free survival with the lenalidomide/R-CHOP combination over control R-CHOP, although response rates were very high (91% overall response rate) in both study arms and median overall survival was not reached. The safety profile of lenalidomide plus R-CHOP was generally well tolerated, with no new safety signals with the addition of lenalidomide.

Relevance
Despite the lack of statistically significant efficacy benefit of lenalidomide with R-CHOP, these study results provide support for ongoing and future analyses to further evaluate the potential effect of pharmacokinetics or dosing, molecular classification, and mutational status in patients with diffuse large B-cell lymphoma.

categorizing them as GCB and non-GCB. GEP-based models recognize a third “unclassified” category that cannot be assigned to either main subtype with sufficient confidence. Patients with ABC-DLBCL treated with R-CHOP historically demonstrated inferior survival (5-year overall survival [OS]: approximately 50% ABC v approximately 80% GCB; \( P < .001 \)). Preclinical studies established lenalidomide’s anti-proliferative activity in ABC-DLBCL cells through increasing interferon-stimulated gene transcription and activation of immunomodulatory mechanisms. Phase II studies showed activity of lenalidomide monotherapy with tolerable safety in relapsed or refractory DLBCL. Coupled with analyses demonstrating a significant clinical response in non-GCB versus GCB-type DLBCL, these studies provided the basis for further evaluation of first-line lenalidomide with R-CHOP (R2-CHOP). Results from two independent, single-arm, phase II studies (REAL07 and MC078E) of R2-CHOP suggested that improved survival may be achieved in non-GCB DLBCL, and with manageable safety. MC078E compared R2-CHOP-treated patients with contemporaneous R-CHOP-only controls, demonstrating that adding lenalidomide may improve survival in non-GCB DLBCL. Longer follow-up of REAL07/MC078E combined non-GCB data showed durable efficacy with 5-year progression-free survival (PFS) of 65% and 5-year OS of 74%. These initial results provided proof-of-concept for ROBUST (ClinicalTrials.gov identifier: NCT02285062; EudraCT number 2013-004054-21), which prospectively compared efficacy and safety of first-line R2-CHOP with placebo/R-CHOP in ABC-type DLBCL.

METHODS

Patients
Eligible patients with CD20+, ABC-type DLBCL were of age 18-80 years, Eastern Cooperative Oncology Group performance status \( \leq 2 \), Ann Arbor stage II-IV disease, and International Prognostic Index (IPI) score of \( \geq 2 \). ABC subtype was determined using the NanoString Lymphoma Subtyping Test performed on NanoString’s nCounter Dx analysis system (NanoString Technologies, Inc, Seattle, WA). Additional eligibility criteria are provided in the Appendix (online only).

Trial Design or Treatments
ROBUST was a multicenter, international, randomized, double-blind, phase III trial (Appendix Fig A1, online only). During screening, the central pathology laboratory confirmed disease diagnosis and CD20 status, and identified COO subtype as ABC or non-ABC (GCB and unclassified). Following eligibility confirmation, patients were stratified by IPI score (2 \( v \geq 3 \)), age (< 65 \( v \geq 65 \) years), and bulky disease (< 7 cm [nonbulky] \( v \geq 7 \) cm [bulky]), and randomly assigned 1:1 to R2-CHOP or placebo/R-CHOP.

Lenalidomide dose was selected based on risk-benefit considerations from proof-of-concept studies (REAL07 and MC078E). Treatment included lenalidomide (or placebo) 15 mg oral on days 1-14 of every 21-day cycle plus R-CHOP21 (rituximab 375 mg/m² intravenous [IV] day 1 or 1, cyclophosphamide 750 mg/m² IV day 1, doxorubicin 50 mg/m² IV day 1, vincristine 1.4 mg/m² [maximum 2.0 mg total] IV day 1, and prednisone [or prednisolone] 100 mg oral days 1-5 [IV day 1 of prednisone or prednisolone, or equivalent methylprednisolone or dexamethasone dose]). Treatment was continued for six cycles, or until intolerability, inadequate response, disease progression, consent withdrawal, or death, whichever occurred first. Two additional rituximab doses (1 dose/21-day cycle) were permitted at cycles 7 and 8 if prespecified and considered standard of care per local practice. Investigators could prospectively give prespecified local radiotherapy consolidation after chemotherapy to treat a particular bulky disease site (\( \geq 7 \) cm) or large mass.

Nowakowski et al
Neutropenia prophylaxis with either granulocyte-colony stimulating factor or granulocyte macrophage-colony stimulating factor was required every cycle per local practices. Additional prophylaxis recommendations are in the Appendix. Growth factor prophylaxis was recommended, and blood product transfusions were allowed per protocol in accordance with ASCO/European Society for Medical Oncology guidelines.26,27

All patients received the same lenalidomide starting dose regardless of baseline creatinine clearance levels. Lenalidomide dose adjustments were planned to manage toxicity (Appendix). Rituximab and chemotherapy dose modifications were allowed per clinical practice of the investigator's institution per approved prescribing information.

The trial adhered to Good Clinical Practice per the International Conference on Harmonisation Guideline E6 under ethical principles of the Declaration of Helsinki. Study conduct followed guidance from each site's institutional review board, independent ethics committee, and regulatory authorities. All patients provided written informed consent before trial enrollment.

**Efficacy and Safety Assessments**

For the primary efficacy analysis, the intent-to-treat population included all randomly assigned patients regardless of receiving study treatment. The primary end point was PFS per 2014 International Working Group criteria28 (amended from the original protocol following 2007 International Working Group criteria29), as assessed by Independent Radiology Adjudication Committee with Food and Drug Administration censoring rules applied.30 Investigators-assessed results provided additional sensitivity analyses.

PFS was defined as the time from random assignment to objective disease progression or death from any cause, whichever occurred first. Secondary end points were event-free survival (EFS; key secondary), OS, response rates, duration of response, time to next lymphoma treatment, and safety. EFS was defined as the time from random assignment to initiation of disease progression, relapse from complete response, initiation of subsequent anti-lymphoma therapy, or death because of any cause. Response assessments included computed tomography and positron emission tomography scans and evaluation of laboratory or clinical data.

The safety population included all patients receiving ≥ 1 dose of any study treatment. Treatment-emergent adverse events (TEAEs) were coded per the Medical Dictionary for Drug Regulatory Activities v21.0 and classified by National Cancer Institute Common Terminology Criteria for Adverse Events v4.03 (tumor flare reaction and skin rash per v3.0).

**Statistical Analyses**

Superiority in PFS was defined as achieving hazard ratio (HR) = 0.625 for R2-CHOP over placebo/R-CHOP (ie, 37.5% risk reduction in disease progression) for an estimated median PFS improvement of 24 months with placebo/R-CHOP to 38 months with R2-CHOP (two-sided \( P < .05 \)). The study was powered to measure 192/560 PFS events for 90% power and included interim futility analysis at 50% (96 events). If the event rate fell < 2 events/mo before reaching 192 events, final analysis was performed when > 170 events occurred (86% power).

Demographics or characteristics and safety were summarized using descriptive statistics, and categorical variables using frequency tabulations. Time-to-event end points using an HR with two-sided 95% CI were estimated by Kaplan-Meier procedure, stratified log-rank test for treatment efficacy, and Cox proportional hazards model. Binary end points (eg, response rate) were summarized in frequency and percent by arm; stratified Cochran-Mantel-Haenszel test evaluated treatment efficacy. All statistical analyses used SAS software version ≥ 9.2 (SAS Institute, Cary, NC).

**RESULTS**

**Patients**

From February 17, 2015 to August 3, 2017, the central pathology laboratory screened samples from 2,109 patients; 570 patients with ABC-DLBCL met eligibility criteria for enrollment at 257 active study centers in 21 countries (Fig 1). Of 2,109 screened patients, exclusions were predominantly because 49% were non-ABC subtype and 24% failed other eligibility criteria (main reasons: 8% inadequate lymph node or biopsy specimen available, 5% non-Ann Arbor stage II-IV, 4% non-IPI ≥ 2, and 3% unable to adhere to protocol requirements, 1% because of a small or insufficient core or tissue biopsy).

In the intent-to-treat analysis, 285 patients in each arm were randomly assigned 1:1 to experimental R2-CHOP and control placebo/R-CHOP groups. Baseline demographics were similar between arms. Overall, patients had a median age of 65 years (52% ≥ 65 and 2% ≥ 80 years of age); 42% IPI 2/58% IPI ≥ 3 score; 88% stage III/IV disease; and 34% bulky disease (Table 1). Median time from initial diagnosis or biopsy date to treatment was 31 days for both arms (R2-CHOP: range, 6-114 days; placebo/R-CHOP: range, 8-98 days). Median follow-up time for all surviving patients was 27.1 months (range, 0-47 months).

Two patients on R2-CHOP and one on placebo/R-CHOP were randomly assigned but never received treatment, and therefore are excluded from the safety population. Adverse events (AEs) were the most frequent reason for discontinuation of lenalidomide or placebo (17% R2-CHOP vs 11% placebo/R-CHOP; Appendix Table A2, online only).

**Efficacy**

**Primary end point.** The primary end point of PFS was not met (HR, 0.85; 95% CI, 0.63 to 1.14; \( P = .29 \); Table 2; Fig 2A). Median PFS was not reached in either arm; 2-year PFS was 67% for R2-CHOP and 64% for placebo/R-CHOP.
Secondary and exploratory efficacy end points. The key secondary efficacy end point EFS was also not met (HR, 1.04 [95% CI, 0.80 to 1.34]; \( P = .73 \)); medians were not reached (Table 2; Fig 2B). EFS included \( n = 10 \) R2-CHOP and \( n = 8 \) placebo/R-CHOP with stable disease or positron emission tomography-positive partial responses who initiated new therapy. OS data were immature; estimated 2-year OS rates were 79% R2-CHOP and 80% placebo/R-CHOP; medians were not reached (Table 2; Fig 2C). Of patients who died, 93/119 deaths (78%) were because of progressive disease (<2% each from AEs or other causes). Overall response rates were 91% for both arms, with 69% versus 65% complete responses for R2-CHOP versus placebo/R-CHOP, respectively (Table 2). Median time to next antilymphoma treatment was not reached in either arm.

Exploratory subgroup analyses of PFS suggested a positive trend in 2-year PFS favoring R2-CHOP (\( \text{v} \) placebo/R-CHOP) in patients with IPI \( \geq 3 \) (59% \( \text{v} \) 50%, \( P = .09 \); Fig 3), nonbulky disease (73% \( \text{v} \) 66%, \( P = .05 \)), and lower baseline creatinine clearance 30 to < 60 mL/min (69% \( \text{v} \) 45%, \( P = .03 \); Fig 4).

Safety

The safety population included 283 R2-CHOP and 284 placebo/R-CHOP patients. Treatment in both arms was given for a median of 18.1 weeks (range, 0.3-29.0 weeks). Overall, 89% of R2-CHOP and 91% of placebo/R-CHOP patients completed six cycles of R-CHOP backbone, and 75% R2-CHOP and 84% placebo/R-CHOP completed six cycles of both lenalidomide or placebo and R-CHOP. The median relative dose intensity of lenalidomide or placebo was 15.0 mg/d for both arms; individual R-CHOP components showed similar dose intensities between arms. More than 80% of patients in both arms received a relative dose intensity of > 90% lenalidomide or placebo. Nearly all patients experienced \( \geq 1 \) any-grade TEAE (99% R2-CHOP and 98% placebo/R-CHOP patients), and 78% R2-CHOP and 71% placebo/R-CHOP patients had \( \geq 1 \) grade \( \geq 3 \) TEAE. Serious TEAEs were observed in 37% R2-CHOP versus 31% placebo/R-CHOP patients. In the respective R2-CHOP versus placebo/R-CHOP arms, dose reductions of lenalidomide or placebo were reported in 26% versus 16% of patients (mainly because of AEs) at a median time to first dose reduction of 72 and 53 days. Dose interruptions of lenalidomide or placebo were reported in 79% versus 73% of patients (mainly because of AEs), and median time to first dose interruption was 22 days for both arms. Discontinuation rates for R2-CHOP versus placebo/R-CHOP, respectively, because of AEs were 17% versus 11%, predominantly because of neutropenia (8% \( \text{v} \) 5%; Appendix Table A2). Dose reductions or delays because of individual R-CHOP components were similar in both arms. Most common grade 3/4 TEAEs (\( \geq 10% \)) for R2-CHOP versus placebo/R-CHOP, respectively, were neutropenia...
(60% v 48%), anemia (22% v 14%), thrombocytopenia (17% v 11%), leukopenia (14% v 15%), febrile neutropenia (14% v 9%), and lymphopenia (11% v 8%; Table 3). More than 89% of patients in each arm received concomitant growth factors throughout the six cycles of study treatment (95% during cycle 1).

During the entire study duration, 57 patients (20%) receiving R2-CHOP and 62 (22%) receiving placebo/R-CHOP died; the primary cause was because of malignant disease or complications thereof (49 [17%] and 44 [16%], respectively; Appendix Table A3, online only). All other causes occurred in < 3% of patients per arm (because of AEs, unknown reasons, second primary malignancies [SPMs], or other). Death was because of SPMs for 2 patients/arm (R2-CHOP: acute myeloid leukemia and squamous cell carcinoma of the tongue; placebo/R-CHOP: lung and gastric adenocarcinomas).

### Table 1. Baseline Demographic and Disease Characteristics (Intent-to-Treat Population)

| Characteristic | R2-CHOP (n = 285) | Placebo/R-CHOP (n = 285) | Total (N = 570) |
|---------------|------------------|------------------------|---------------|
| Median age, years (range) | 65 (21-82) | 65 (28-83) | 65 (21-83) |
| Age ≥ 65a | 147 (52) | 148 (52) | 295 (52) |
| Age ≥ 70 | 94 (33) | 91 (32) | 185 (32) |
| Age ≥ 80 | 8 (3) | 6 (2) | 14 (2) |
| Male sex | 164 (58) | 143 (50) | 307 (54) |
| ECOG PSb | | | |
| 0 | 129 (45) | 111 (39) | 240 (42) |
| 1 | 104 (36) | 118 (41) | 222 (39) |
| 2 | 52 (18) | 56 (20) | 108 (19) |
| Ann Arbor stage | | | |
| II | 37 (13) | 33 (12)c | 69 (12) |
| III | 80 (28) | 98 (34) | 178 (31) |
| IV | 168 (59) | 154 (54) | 322 (56) |
| IPI risk scorea | | | |
| Intermediate (2) | 121 (42) | 120 (42) | 241 (42) |
| High (3-5) | 164 (58) | 165 (58) | 329 (58) |
| Bulky disease (≥ 7 cm)a | 97 (34) | 99 (35) | 196 (34) |
| CrCl, mL/min | | | |
| ≥ 30 to < 60 | 41 (14) | 39 (14) | 80 (14) |
| ≥ 60 | 244 (86) | 245 (86) | 489 (86) |
| Missing | 0 (0) | 1 (0.4) | 1 (0.2) |
| Elevated LDHc | 177 (62) | 176 (62) | 353 (62) |
| Received two extra prespecified doses of rituximab | 154 (54) | 155 (54) | 309 (54) |
| Received prespecified consolidation radiotherapy | 17 (6) | 8 (3) | 25 (4) |
| Geographic distribution | | | |
| Europe | 124 (44) | 150 (53) | 274 (48) |
| Asia-Pacific | 111 (39) | 92 (33) | 203 (36) |
| North America | 24 (8) | 23 (8) | 47 (8) |
| Other | 26 (9) | 20 (7) | 46 (8) |

**Note.** All data are no. (%) unless otherwise stated. There were no significant between-group differences in the characteristics evaluated at baseline. Percentages may not sum to 100 because of rounding.

Abbreviations: CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.

aPatient stratification factors.

bAn ECOG PS score of 0 indicates no symptoms and 1 indicates mild symptoms; higher scores indicate greater disability.

cIncluded one patient with ineligible stage I disease and one missing patient in the placebo plus R-CHOP arm.

dElevated LDH levels were > 234 U/L.
In patients with ABC-DLBCL from ROBUST, adding lenalidomide to R-CHOP did not improve efficacy over placebo/R-CHOP. Response rates were very high (91% overall response rate) overall, median OS was not reached, and survival or SPMs continue to be followed. The R2-CHOP safety profile was generally well tolerated (no new safety signals), consistent with known profiles for individual agents.

At a median 27.1-month follow-up for survivors, placebo/R-CHOP results were interesting in that control patients had better outcomes than originally projected. Median PFS/OS were not reached; 2-year PFS and OS were 64% and 80%, respectively. Longer PFS for control patients were recently confirmed by the GOYA study, evaluating cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab or obinutuzumab; median PFS was not reached for patients with ABC-DLBCL (median 29-month follow-up), and 3-year PFS was 58% R-CHOP and 61% obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.10 Multiple studies showed that R-CHOP-treated patients with ABC or non–GCB-type DLBCL expect to have 2-year PFS of ≈ 40% and 2-year OS of approximately 50%,16,24 whereas more recent studies experienced a similar phenomenon to ROBUST. Bortezomib plus R-CHOP failed to show improved PFS over R-CHOP in non-GCB patients (per IHC) from the PYRAMID phase II study (2-year PFS: 78% R-CHOP v 82% bortezomib/R-CHOP) or in the REMoDL-B phase III study of patients with ABC-DLBCL (per GEP), with 30-month PFS of 65% R-CHOP versus 73% bortezomib/R-CHOP.7 The randomized phase III PHOENIX study of ibrutinib/R-CHOP versus placebo/R-CHOP was similarly disappointing with no significant difference between arms for the EFS primary end point (or other survival end points) in either non-GCB patients prospectively selected by IHC or ABC patients retrospectively evaluated by GEP.9 Exploratory analyses from PHOENIX identified a treatment interaction for EFS, PFS, and OS favoring the ibrutinib-containing arm in patients,60 years of age. Additional exploratory evaluations of PFS and OS in ROBUST based on age cutoffs of < 60 and ≥ 60 years of age showed no significant treatment interaction (Fig 4, Appendix Fig A2, online only). Although these independent phase II-III studies used various techniques for identifying non-GCB or ABC types, interestingly, R-CHOP control arms performed similarly to the active treatment arm, and with OS rates ≥ 80% after 2-3 years of follow-up.7,9

In ROBUST, there was a positive trend for PFS favoring R2-CHOP in 58% of patients with IPI score ≥ 3. This trend was not observed in the E1412 study, although IPI cutoffs evaluated in E1412 varied by including IPI groups of 2-3 versus 4-5.31 Despite the difference, we continue to believe that IPI prognostic factors remain valid in the post-rituximab era for patients receiving R-chemotherapy-based treatment.

### Table 2. Efficacy Outcomes (Intent-to-Treat Population)

| Variable | R2-CHOP (n = 285) | Placebo/R-CHOP (n = 285) | HR (95% CI) | P |
|----------|------------------|-------------------------|-------------|---|
| Median PFS as assessed by IRAC, months (95% CI) | NR (NR to NR) | NR (35.5 to NR) | 0.85 (0.63 to 1.14) | .29 |
| PFS probability at 2 years, % (SE) | 67 (3) | 64 (3) | — | — |
| Median EFS as assessed by IRAC, months (95% CI) | NR (NR to NR) | NR (31.3 to NR) | 1.04 (0.80 to 1.34) | .73 |
| EFS probability at 2 years, % (SE) | 59 (3) | 61 (3) | — | — |
| Median OS, months (95% CI) | NR (NR to NR) | NR (NR to NR) | 0.93 (0.65 to 1.32) | .64 |
| OS probability at 2 years, % (SE) | 79 (2.5) | 80 (2.5) | — | — |
| Best response as assessed by IRAC | | | | |
| ORR, no. (% [95% CI]) | 259 (91 [87 to 94]) | 259 (91 [87 to 94]) | — | 1.00 |
| CR, no. (% [95% CI]) | 197 (69 [63 to 74]) | 185 (65 [59 to 70]) | — | .29 |
| PR, no. (%) | 62 (22) | 74 (26) | — | — |
| SD, no. (%) | 6 (2) | 2 (1) | — | — |
| PD, no. (%) | 5 (2) | 4 (1) | — | — |
| Unevaluable, no. (%)a | 15 (5) | 20 (7) | — | — |
| Median DOR as assessed by IRAC, months (95% CI) | NR (NR to NR) | NR (33.7 to NR) | 0.85 (0.62 to 1.16) | .31 |
| Median TTNLT as assessed by IRAC, months (95% CI) | NR (NR to NR) | NR (NR to NR) | 1.17 (0.86 to 1.59) | .32 |

NOTE. Data cutoff: March 15, 2019.

Abbreviations: CR, complete response; DOR, duration of response; EFS, event-free survival; HR, hazard ratio; IRAC, Independent Radiology Adjudication Committee; NR, not reached; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP; SD, stable disease; SE, standard error; TTNLT, time to next antilymphoma treatment.

aPatients were unevaluable because of missing post-baseline response assessments; patients still contributed to time-to-event analyses.

### Discussion

In patients with ABC-DLBCL from ROBUST, adding lenalidomide to R-CHOP did not improve efficacy over placebo/R-CHOP. Response rates were very high (91% overall response rate) overall, median OS was not reached, and survival or SPMs continue to be followed. The R2-CHOP safety profile was generally well tolerated (no new safety signals), consistent with known profiles for individual agents.

At a median 27.1-month follow-up for survivors, placebo/R-CHOP results were interesting in that control patients had better outcomes than originally projected. Median PFS/OS were not reached; 2-year PFS and OS were 64% and 80%, respectively. Longer PFS for control patients were recently confirmed by the GOYA study, evaluating cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab or obinutuzumab; median PFS was not reached for patients with ABC-DLBCL (median 29-month follow-up), and 3-year PFS was 58% R-CHOP and 61% obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.10 Multiple studies showed that R-CHOP-treated patients with ABC or non–GCB-type DLBCL expect to have 2-year PFS of ≈ 40% and 2-year OS of approximately 50%,16,24 whereas more recent studies experienced a similar phenomenon to ROBUST. Bortezomib plus R-CHOP failed to show improved PFS over R-CHOP in non-GCB patients (per IHC) from the PYRAMID phase II study (2-year PFS: 78% R-CHOP v 82% bortezomib/R-CHOP) or in the REMoDL-B phase III study of patients with ABC-DLBCL (per GEP), with 30-month PFS of 65% R-CHOP versus 73% bortezomib/R-CHOP. The randomized phase III PHOENIX study of ibrutinib/R-CHOP versus placebo/R-CHOP was similarly disappointing with no significant difference between arms for the EFS primary end point (or other survival end points) in either non-GCB patients prospectively selected by IHC or ABC patients retrospectively evaluated by GEP. Exploratory analyses from PHOENIX identified a treatment interaction for EFS, PFS, and OS favoring the ibrutinib-containing arm in patients < 60 years of age. Additional exploratory evaluations of PFS and OS in ROBUST based on age cutoffs of < 60 and ≥ 60 years of age showed no significant treatment interaction (Fig 4, Appendix Fig A2, online only). Although these independent phase II-III studies used various techniques for identifying non-GCB or ABC types, interestingly, R-CHOP control arms performed similarly to the active treatment arm, and with OS rates ≥ 80% after 2-3 years of follow-up.7,9 In ROBUST, there was a positive trend for PFS favoring R2-CHOP in 58% of patients with IPI score ≥ 3. This trend was not observed in the E1412 study, although IPI cutoffs evaluated in E1412 varied by including IPI groups of 2-3 versus 4-5. Despite the difference, we continue to believe that IPI prognostic factors remain valid in the post-rituximab era for patients receiving R-chemotherapy-based treatment.
Prior studies of lenalidomide in DLBCL supported prioritizing treatment in ABC-type patients based on disease biology and clinical benefit. However, there appears to be additional complexity within COO subtypes, leading to possible variable outcomes independent of IPI. Regional variability in ABC-type patient proportions worldwide may also contribute some differences, although this remains to be determined with further study. Based on molecular classifier analyses within ABC type, further subgroups may show differential outcomes. Ongoing analyses of biomarker and mutational profiles for ROBUST’s ABC patients will help identify whether variable genetic profiles affected outcomes. Moreover, further classification of types may help provide a biologic basis for novel/novel drug combinations in DLBCL.

A potential limitation here was median time from initial diagnosis (or first biopsy) to treatment initiation. Although COO sample identification was streamlined to 2.4 calendar days for time from central pathology sample receipt to COO results being provided to the study site, median time from diagnosis to treatment initiation was longer at 31 days. In this global study, many patients were referred from smaller community practices to treatment centers. It is a common practice for referral centers to re-review pathology considering diagnostic difficulties in non-Hodgkin lymphoma. This can cause an additional delay, apart from the need to access and submit tissue for central review and COO assay. Similarly, many referral centers require fluorescent in situ hybridization for double-hit or triple-hit lymphoma, typically not done at community practices for additional delays. It is possible that this longer time may have led to selection bias.

FIG 2. PFS, EFS, and OS in the intent-to-treat population: (A) progression-free survival by Independent Radiology Adjudication Committee (IRAC) assessment; (B) event-free survival by IRAC assessment; (C) OS. EFS, event-free survival; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.
for patients with less high-risk disease. Recently, the E1412 study of first-line R2-CHOP versus R-CHOP alone reported a median time from diagnosis to treatment of 21 days; patients were enrolled without prospective COO selection, and efficacy outcomes showed a significant PFS difference between arms, irrespective of COO subtype.31 Recently reported evidence from large patient cohorts from the University of Iowa and Mayo Clinic (n = 986) and LYSA LNH-2003 (n = 1,444) showed that diagnosis-to-treatment interval (DTI) was an important clinical factor in newly diagnosed DLBCL.36 Patients who received anthracycline-based immunochemotherapy demonstrated a significant

FIG 3. PFS based on IPI status (A) IPI = 2 and (B) IPI ≥ 3 (intent-to-treat population). HR, hazard ratio; IPI, International Prognostic Index; PFS, progression-free survival; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.

FIG 4. Subgroup analyses of progression-free survival by Independent Radiology Adjudication Committee in the intent-to-treat population treated with R2-CHOP versus placebo/R-CHOP. aPrespecified stratification factor. CrCl, creatinine clearance; DLBCL, diffuse large B-cell lymphoma; HR, hazard ratio; IPI, International Prognostic Index; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.
association between shorter DTI, worse clinical factors (elevated lactate dehydrogenase, poor Eastern Cooperative Oncology Group performance status, B symptoms, and higher IPI) and lower EFS rate at 24 months. The converse was also true; patients with longer DTI demonstrated improved 24-month EFS, meaning that longer times to initiate treatment represented a higher willingness to wait for treatment (ie, lower-risk disease, better overall health, and fitness), increasing the likelihood of better outcomes. A similar association was reported in GOYA study patients; shorter PFS was observed for patients with

$15 \text{ days from diagnosis to random assignment and } 8 \text{ days from diagnosis to screening, potentially because of higher-risk disease.}^{37}$

Although REAL07 and MC078E phase II studies of lenalidomide + R2-CHOP suggested similar outcomes despite different dosing schema,$^{23,24}$ a potential limitation in ROBUST may be from the lower total lenalidomide dose. Indeed, studies in relapsed or refractory DLBCL demonstrating activity of single-agent lenalidomide mainly used the dose of 25 mg daily. However, other studies have used the 20 mg daily dose with rituximab,$^{38}$ the proper lenalidomide dose in combination with other agents remains an open issue.

Overall, the safety profile for both ROBUST arms was as expected, with no new safety findings. Most patients completed six cycles in both arms (74% R2-CHOP and 84% placebo/R-CHOP), with 80% of patients receiving $>90\%$ relative dose intensity of lenalidomide or placebo. The most common grade 3/4 TEAEs were neutropenia, anemia, and thrombocytopenia for both arms, although $89\%$ of patients received concomitant growth factors throughout treatment.

Despite the lack of benefit of lenalidomide with R-CHOP observed here, ongoing and future analyses will further evaluate the potential effect of pharmacokinetics or dosing, molecular classification, and mutational status. The meaning of IPI findings and why worse prognosis patients had better PFS when receiving lenalidomide remain to be further elucidated. It is also important to address the role of timing from diagnosis to initial treatment and further evaluate genetic classifiers that may inherently affect outcomes. These data will broaden our understanding to support future assessments of next-generation immunomodulatory agents (CELMoDs), which have displayed promising preclinical activity in B-cell lymphoma.$^{18}$

**AFFILIATIONS**

$^{\dagger}$Division of Hematology, Mayo Clinic, Rochester, MN

$^{\ddagger}$Division of Hematology, A.O.U. Citt`a della Salute e della Scienza Hospital and University, Torino, Italy

### TABLE 3. TEAEs During the Treatment Period in the Safety Population (≥ 15% Any Grade and Adverse Events of Interest)

| TEAEs                        | R2-CHOP (n = 283) | Placebo/R-CHOP (n = 284) |
|------------------------------|-------------------|---------------------------|
|                              | Any Grade         | Grade ≥ 3                 | Any Grade         | Grade ≥ 3                 |
| Neutropenia                  | 189 (67)          | 169 (60)                  | 153 (54)          | 137 (48)                  |
| Febrile neutropenia*         | 39 (14)           | 39 (14)                   | 25 (9)            | 25 (9)                    |
| Anemia                       | 128 (45)          | 63 (22)                   | 101 (36)          | 39 (14)                   |
| Constipation                 | 92 (33)           | 1 (< 1)                   | 81 (29)           | 0 (0)                     |
| Thrombocytopenia             | 72 (25)           | 47 (17)                   | 55 (19)           | 32 (11)                   |
| Nausea                       | 65 (23)           | 3 (1)                     | 67 (24)           | 4 (1)                     |
| Pyrexia                      | 58 (20)           | 0 (0)                     | 46 (16)           | 10 (4)                    |
| Diarrhea                     | 52 (18)           | 6 (2)                     | 42 (15)           | 3 (1)                     |
| Peripheral sensory neuropathy| 51 (18)           | 1 (< 1)                   | 51 (18)           | 5 (2)                     |
| Leukopenia                   | 50 (18)           | 40 (14)                   | 50 (18)           | 42 (15)                   |
| Alopecia                     | 48 (17)           | 0 (0)                     | 43 (15)           | 0 (0)                     |
| Fatigue                      | 40 (14)           | 5 (2)                     | 50 (18)           | 3 (1)                     |
| Infusion-related reaction*    | 28 (10)           | 2 (< 1)                   | 33 (12)           | 8 (3)                     |
| Deep vein thrombosis*        | 4 (1)             | 2 (< 1)                   | 4 (1)             | 2 (< 1)                   |
| Tumor lysis syndrome*        | 2 (< 1)           | 1 (< 1)                   | 1 (< 1)           | 1 (< 1)                   |

**NOTE.** Data are given as no. (%).

Abbreviations: R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP; TEAE, treatment-emergent adverse event.

*Denotes an adverse event of interest.

*For the four patients in each arm with any-grade deep vein thrombosis, prophylaxis was low-molecular-weight heparin for two patients, nonsteroidal anti-inflammatory drug for one patient, and one patient received no prophylaxis.
Authors' disclosures of potential conflicts of interest
Disclosures provided by the authors are available with this article at DOI:
https://doi.org/10.1200/JCO.20.01366.

Data sharing statement
Data requests may be submitted to Celgene, A Bristol Myers Squibb Company at https://vivli.org/ourmember/celgene/ and must include a description of the research proposal.

Author contributions
Conception and design: Grzegorz S. Nowakowski, Annalisa Chiappella, David W. Scott, Wojciech Jurczak, Jun Zhu, Myron Czuczman, Thomas E. Witzig, Umberto Vitolo
Provision of study materials or patients: Wojciech Jurczak, Jie Jin, Juan Miguel Bergua, Francesco Piazza, Anna Lia Molinari, Kazuhito Yamamoto
Collection and assembly of data: Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David W. Scott, Qingyuan Zhang, Muhit ¨Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan Miguel Bergua, Francesco Piazza, Heidi Mocikova, Anna Lia Molinari, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Thomas E. Witzig, Umberto Vitolo
Data analysis and interpretation: Grzegorz S. Nowakowski, Annalisa Chiappella, David W. Scott, Jie Jin, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E. Witzig, Umberto Vitolo

Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

Acknowledgments
We would like to dedicate this work to the memory of Bertrand Coiffter after his untimely passing. Prof Coiffer was a foremost expert in the field and has our utmost respect for his significant contributions to the work of the ROBUST study and to the field overall. Thank you to patients, families, caregivers, and investigators who participated in the ROBUST clinical study. Thank you to the Fondazione Italiana Linfomi (FIL) and Mayo Clinic for providing significant contributions and support for the study. Thank you to the international board of expert pathologists for providing histopathology review, and independent expert hematologist for clinical assessment and imaging review. Thank you to the data monitoring committee (DMC) that served as an independent expert advisory group to evaluate safety and efficacy throughout the study, including Bertrand Coiffer, MD (chair); Martin Dreyling MD; David Maloney MD, PhD; John Leonard MD; and Weichung Shih, PhD. The authors received editorial support in the preparation of this manuscript from Julie Kern, PhD, CMPP of Bio Connections LLC, funded by Celgene Corporation. The authors directed development of the manuscript and are fully responsible for all content and editorial decisions for this manuscript.

Corresponding author
Grzegorz S. Nowakowski, MD, Division of Hematology, Mayo Clinic, 201 First Street SW, Rochester, MN 55902; e-mail: Nowakowski.Grzegorz@mayo.edu.

Study groups
A comprehensive list of ROBUST study investigators and institutions is shown in Appendix Table A1 (online only).

Prior presentation
Presented in part as an oral presentation (abstract #005) at the 2019 International Conference for Malignant Lymphoma, Lugano, Switzerland, June 18-22, 2019.

Support
Supported by Celgene Corporation, a Bristol-Myers Squibb Company, Princeton, NJ. This study was conducted with the scientific support of the Fondazione Italiana Linfomi and the Mayo Clinic.

Clinical trial information
ClinicalTrials.gov identifier: NCT02285062; EudraCT 2013-004054-21.

References
1. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin’s lymphoma classification project. J Clin Oncol 16:2780-2795, 1998
2. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, International Agency for Research on Cancer, 2008
3. Coffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002

4. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large-B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006

5. Tilly H, Gomes da Silva M, Vito U, et al: Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v11-v125, 2015 (suppl 5)

6. Wang Y, Farrow Q, Link BK, et al: Late relapses in patients with diffuse large B-cell lymphoma treated with immunechemotherapy. J Clin Oncol 37:1819-1827, 2019

7. Davies A, Cummin TE, Barrans S, et al: Gene-expression profiling of bortezomib added to standard chemomunotherapy for diffuse large B-cell lymphoma (REMOdL-B): An open-label, randomised, phase 3 trial. Lancet Oncol 20:649-662, 2019

8. Leonard JP, Kolibaba KS, Reeves JA, et al: Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol 35:3538-3546, 2017

9. Younges A, Sehn LH, Johnson P, et al: Randomized phase III trial of bortezomib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 37:1285-1295, 2019

10. Vito U, Trneny M, Belada D, et al: Ubinituzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol 35:3529-3537, 2017

11. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000

12. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotheraphy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002

13. Scott DW, Wright GW, Williams PM, et al: Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123:1214-1217, 2014

14. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004

15. Wright G, Tan B, Rosenwald A, et al: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 100:9999-9996, 2003

16. Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large-B-cell lymphomas. Nature 425:239-245, 2003

17. Chamberlain PP, Lopez-Girona A, Miller K, et al: Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol 21:803-809, 2014

18. Hagner PR, Man HW, Fontanilco C, et al: CC-122, a pleotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood 126:779-789, 2015

19. Zhang LH, Kosik J, Wang M, et al: Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 160:487-502, 2013

20. Wiernik PH, Lossos IS, Tuscano JM, et al: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 26:4952-4957, 2008

21. Wiltzi TE, Vose JM, Zinzani PL, et al: An international phase II study of single-agent lenalidomide in relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 22:1622-1627, 2011

22. Hernandez-Hilaliutri FJ, Deeb G, Zinzani PL, et al: Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminat center B-cell-like than in germinal center B-cell-like phenotype. Cancer 117:5058-5066, 2011

23. Vito U, Chiappella A, Franceschetti S, et al: Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: Results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 15:730-737, 2014

24. Nowakowski GS, LaPlant BR, Witzig TE, et al: Randomized phase II study of R-Chop versus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma: A phase II study. J Clin Oncol 33:251-257, 2015

25. Castellino A, Chiappella A, LaPlant BR, et al: Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): Long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J 8:108, 2018

26. Crawford J, Caserta C, Roila F, et al: Hematopoietic growth factors: ESMO clinical practice guidelines for the application. Ann Oncol 21:v248-v251, 2010 (suppl 5)

27. Smith TJ, Bohle K, Lyman GH, et al: Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199-3212, 2015

28. Cheson BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059-3068, 2014

29. Cheson BD, Pfisther B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007

30. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (US): Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville, MD, US Food and Drug Administration, 2007

31. Nowakowski GS, Hong F, Scott DW, et al: Addition of lenalidomide to R-CHOP (R2CHOP) improves outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL): First report of ECOG-ACRIN1412 a randomized phase 2 US intergroup study of R2CHOP vs R-CHOP. Hernaitol Oncol (ICML Abstract) 37:37-38, 2019 (suppl; abstr 006)

32. Shipp MA, Harrington DP, Anderson SD, et al: A predictive model for aggressive non-Hodgkin's lymphoma: International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993

33. Ziepert M, Hasenclever D, Kuhnt E, et al: Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28:2373-2380, 2010

34. Chapuy B, Steward C, Dunford AJ, et al: Molecular subtypes of diffuse large B-cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679-690, 2018

35. Nowakowski GS, Chiappella A, Witzig TE, et al: Variable global distribution of cell-of-origin from the ROBUST phase 3 study in diffuse large B-cell lymphoma. Blood Cancer J 8:108, 2018

36. Maurer MJ, Ghesquieres H, Link BK, et al: Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol 36:1603-1610, 2018

37. Szafer-Glusman E, Liu J, Peale FV Jr, et al: A simulation analysis to evaluate the effect of prospective biomarker testing on progression-free survival (PFS) in DLBCL. Blood 130:abstract 419, 2017
38. Zinzani PL, Pellegrini C, Gandolfi L, et al: Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 trial. Clin Lymphoma Myeloma Leuk 11:462-466, 2011
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wcs or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Grzegorz S. Nowakowski
Consulting or Advisory Role: Celgene, MorphoSys, Genentech, Selvita, Debiopharm Group, Kite/Gilead
Research Funding: Celgene, NanoString Technologies, MorphoSys
Annalisa Chiappella
Honoraria: Celgene, Gilead-Kite, Janssen Oncology, Roche, Servier
Consulting or Advisory Role: Celgene, Gilead-Kite, Janssen-Cilag, Takeda, iQone

David W. Scott
Consulting or Advisory Role: Celgene, Janssen, Abbvie, AstraZeneca
Research Funding: Janssen, Roche/Genentech, NanoString Technologies

Patents, Royalties, Other Intellectual Property: Named inventor on a pending patent describing gene expression profiling in prognosis in classical Hodgkin lymphoma. As a member of the LLMPP I am potentially a named inventor on a pending patent on the use of gene expression profiling to assign cell-of-origin in diffuse large B-cell lymphoma. I am a named inventor on a pending patent on the use of gene expression profiling to determine the proliferation signature in mantle cell lymphoma. Named inventor on a pending patent describing use of gene expression profiling to identify molecular subtypes of GC-BCLCL.

Wojciech Jurczak
Consulting or Advisory Role: Janssen-Cilag, Acerta Pharma/AstraZeneca, Merck, Loxo, TG Theraerapeutics, BeiGene

Muhit Özcan
Honoraria: Takeda
Research Funding: Janssen, Celgene, Takeda, Bayer, Merck, Archigen Biotech, Roche, Pharmacyclics, Abbvie
Travel, Accommodations, Expenses: Takeda, Sanofi, Roche, Bristol-Myers Squibb, Abdi Ibrahim, Amgen, Janssen

David Belada
Consulting or Advisory Role: Roche, Gilead Sciences, Janssen-Cilag, Takeda, MorphoSys, Debiopharm Group
Research Funding: Roche, Gilead Sciences, Janssen-Cilag, Takeda, MorphoSys, Pharmacyclics, Archigen Biotech
Travel, Accommodations, Expenses: Gilead Sciences, Takeda, Roche

Juan Miguel Bergua
Consulting or Advisory Role: Daiichi Sankyo
Travel, Accommodations, Expenses: Roche/Genentech

Dok Hyun Yoon
Honoraria: Celltrion, Roche, Janssen, Amgen, Celgene, Samyang, Kirin Pharmaceuticals
Consulting or Advisory Role: Roche, Janssen, Amgen, Celgene, Green Cross
Research Funding: Samyang, Abctone, Roche/Genentech, Janssen Oncology, Amgen, Gennab, Botyung

Federica Cavalo
Honoraria: Takeda, Janssen-Cilag, Gilead Sciences
Consulting or Advisory Role: Janssen-Cilag, Gilead Sciences
Travel, Accommodations, Expenses: Celgene

Kazuhito Yamamoto
Honoraria: Kyowa Hakko Kirin, Takeda, Janssen, Bristol-Myers Squibb, Celgene, Sumitomo Dainippon, Ono Pharmaceutical, Chugai Pharma, Novartis, Otsuka, Mundipharma, Eisai, MSD, Meiji Seika Kaisha; Sanofi, Nippon Shin'yaku, Abbvie, GlaxoSmithKline
Consulting or Advisory Role: Ono Pharmaceutical, Meiji Seika Kaisha, Chugai Pharma, Bristol-Myers Squibb, Kyowa Hakko Kirin, Takeda, Celgene, HUYA Bioscience International, Stemline Therapeutics, Eisai, Janssen, AstraZeneca, Daiichi Sankyo, Abbvie
Research Funding: Chugai Pharma, Novartis, ARAD, Takeda, Gilead Sciences, Abbvie, Ono Pharmaceutical, Celgene, Solasia Pharma, MSD, Eisai, Zenyaku

Kogyo, Bayer, SymBio Pharmaceuticals, AstraZeneca, Incyte, Mundipharma, Yakult Pharmaceutical

Koji Iizutsu
Honoraria: Takeda, Chugai Pharma, Eisai, Janssen, Abbvie, Novartis, MSD, Dainippon Sumitomo Pharma, Ono Pharmaceutical, Mundipharma, HUYA Bioscience International, AstraZeneca, Bayer, Bristol-Myers Squibb, Kyowa Hakko Kirin, Fujifilm, Celgene
Consulting or Advisory Role: Bayer, Celgene, AstraZeneca
Research Funding: Eisai, Chugai Pharma

Koji Kato
Honoraria: Takeda, MSD, Kyowa-Kirin, Janssen, Celgene, Ono, Mundippon-Sumitomo, Bristol-Myers Squibb
Consulting or Advisory Role: Abbvie, AstraZeneca, Celgene, Chugai, Eisai, Janssen, Novartis, Daiichi Sankyo
Research Funding: Chugai, Takeda, Kyowa Kirin, Abbvie, Novartis, Eisai, Janssen, Celgene, Ono, Novartis, Daiichi Sankyo

Myron Czuczman
Employment: Celgene
Stock and Other Ownership Interests: Celgene
Other Relationship: Bristol-Myers Squibb

Sarah Hersey
Stock and Other Ownership Interests: Novartis, Johnson & Johnson, Bristol-Myers Squibb

Adrian Kilcoyne
Employment: Celgene
Stock and Other Ownership Interests: Celgene

Jacqueline Russo
Employment: Celgene/Bristol-Myers Squibb, Kite Pharma
Stock and Other Ownership Interests: Celgene/Bristol-Myers Squibb, Kite Pharma

Krista Hudak
Employment: Bristol-Myers Squibb, Novartis
Stock and Other Ownership Interests: Bristol-Myers Squibb, Novartis

Jingshan Zhang
Employment: Celgene
Stock and Other Ownership Interests: Bristol-Myers Squibb
Travel, Accommodations, Expenses: Celgene

Steve Wade
Employment: Bristol-Myers Squibb
Stock and Other Ownership Interests: Bristol-Myers Squibb

Thomas E. Witzig
Consulting or Advisory Role: Karyopharm Therapeutics, Abbvie/Genentech, Seattle Genetics, Celgene, Incyte, Epizyme, Cellectar, Tessa Therapeutics, Portola Pharmaceuticals, MorphoSys, ADC Therapeutics
Research Funding: Celgene, Acerta Pharma, Kura Oncology, Acrotech Biopharma, Karyopharm Therapeutics

Patents, Royalties, Other Intellectual Property: I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note—simply filed—not even close to being granted.

Umberto Vitolo
Consulting or Advisory Role: Gilead Sciences, Janssen, Celgene, Regeneron Speakers’ Bureau: Gilead Sciences, Celgene, Abbvie, Roche, Janssen Oncology
Travel, Accommodations, Expenses: Gilead Sciences, Roche

No other potential conflicts of interest were reported.
SUPPLEMENTAL METHODS

Patients
Patients with unclassified or germinal center B-cell-like (GCB)-type diffuse large B-cell lymphoma (DLBCL) were excluded. Patient tissue biopsies were prospectively evaluated by central pathology to confirm CD20+, ABC-type DLBCL status. Cell-of-origin (COO) type and histology were analyzed from formalin-fixed, paraffin-embedded excisional or surgical or core needle biopsy samples. Histology was classified by the following World Health Organization 2008 subclassifications: not otherwise specified (NOS), associated with chronic inflammation, or with positive Epstein-Barr virus in the elderly. Patient age was 18-80 years; patients older than 80 years could be included if their Eastern Cooperative Oncology Group (ECOG) performance status (PS) was ≤ 1, each individual organ system score was ≤ 2 per the modified Cumulative Illness Rating Scale for comorbidities, and patients were otherwise eligible for full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) per local practices. Additional patient inclusion criteria included: ECOG PS ≤ 2; Ann Arbor stage II-IV disease; International Prognostic Index (IPI) score of ≥ 2; bi-dimensionally measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) with at least one lesion ≥ 1.5 cm in the longest diameter and measurable in two perpendicular directions; and candidacy for six cycles of R-CHOP21. Laboratory requirements were the following: absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L; platelets ≥ 75 × 10^9/L; hemoglobin ≥ 7.5 g/dL (4.7 mmol/L); serum aspartate or alanine transaminase ≤ 3.0 upper limit of normal (ULN); serum total bilirubin ≤ 2.0 mg/dL (34 µmol/L); and calculated creatinine clearance (Cockcroft-Gault formula) of ≥ 30 mL/min.

Two negative pregnancy tests were required for females of child-bearing potential, and all patients were required to prevent pregnancy via abstinence or use of contraception. Exclusion criteria were unclassified or GCB-type DLBCL; active central nervous system or meningeal lymphoma; post-transplant lympho-proliferative disorders; transformed NHL or composite DLBCL or follicular lymphoma; active infection with hepatitis B or C or human immunodeficiency virus; left ventricular ejection fraction < 45%; grade ≥ 2 peripheral neuropathy; history of other malignancies (unless disease-free for ≥ 5 years); life expectancy < 6 months; unwillingness to take venous thromboembolic prophylaxis; and prior use of lenalidomide.

Trial Design and Treatments
The lenalidomide dose was selected based on risk-benefit considerations from two proof-of-concept studies, which administered lenalidomide 15 mg/day, days 1-14 in the REAL07 study and 25 mg/day, days 1-10 in the MC078E study.23,24 Because the efficacy outcomes were similar, the lower dose from the REAL07 study was selected for ROBUST based on the best data on feasibility and lower incidence of severe adverse events (AEs), suggesting a better benefit-risk profile.

Lenalidomide dose reductions to the following levels were allowed: 10, 5, and 2.5 mg. If lenalidomide dosing was interrupted for toxicity or the cycle delayed, lenalidomide could be restarted only if the laboratory parameters recovered as follows: ANC ≥ 1.0 × 10^9/L; platelet count ≥ 75 × 10^9/L; and any other nonhematologic AE resolved to grade ≤ 2 (except where noted below). A mandatory lenalidomide hold was required in the instance of grade 4 neutropenia lasting ≥ 7 days or grade 3/4 febrile neutropenia, grade 4 thrombocytopenia, grade 2 or 3 nonesquamating rash, grade 2 allergic reaction or hypersensitivity, grade ≥ 3 constipation, grade ≥ 3 venous thrombosis or embolism, grade ≥ 2 tumor lysis syndrome, elevated aspartate or alanine transferase (> 3 × ULN) or bilirubin (> 3 × ULN), or another grade ≥ 3 nonhematologic AE. Lenalidomide was permanently discontinued in the instance of grade ≥ 3 desquamating or grade 4 non-desquamating rash, and grade ≥ 3 allergic reaction or hypersensitivity. For other, lenalidomide-related nonhematologic AEs grade ≥ 3, lenalidomide was withheld until the AE resolved to grade ≤ 2, and then restarted at the same or next lower dose level per the investigator’s discretion.

For patients at risk for CNS involvement, CNS lymphoma prophylaxis with four to eight doses of concomitant intrathecal methotrexate and/or cytarabine during study treatment was recommended. Patients were recommended to receive prophylaxis for tumor lysis syndrome (alo-purinol, rasburicase, or equivalent per institutional guidelines) and be well hydrated during the first week of treatment. For patients at high risk for a venous thromboembolic event, prophylactic anticoagulation therapy with low-molecular-weight heparin, heparin, or warfarin was recommended. Premedication with an antemetic for nausea prophylaxis, acetaminophen or diphenhydramine for rituximab infusion reaction prophylaxis, and prophylaxis for Pneumocystis were permitted per local practice. Growth factor and blood product transfusions were allowed during treatment and follow-up periods, and were used in accordance with the American Society of Clinical Oncology/European Society for Medical Oncology guidelines.26,27

Efficacy and Safety Assessments
The key secondary end point was event-free survival, which was defined as the time from random assignment to initiation of disease progression, relapse from complete response (CR), initiation of subsequent antilymphoma therapy, or death because of any cause. CR was defined as the percentage of patients who ever achieved a CR after initiating study treatment and prior to initiation of subsequent antilymphoma treatment.

Response assessments included CT and positron emission tomography scans and evaluation of laboratory or clinical data after cycle 3; once 3-4 weeks after completing cycle 6; every 12 weeks from week 34 to 154 (± 1 week); and weeks 180, 206, 258, and 310 (± 2 weeks) until first progression.

Supplemental Results

Futility analysis.
An interim futility analysis of PFS at the 50% information level (96 events) was performed with a data cutoff of June 30, 2017. The data monitoring committee (composed of independent, external oncologists and a biostatistician) met on November 6, 2017, to review the interim analysis data and agreed to allow the study to continue as planned.

Safety.
The incidence of treatment-emergent adverse events (TEAEs) was analyzed for patients by age < 65 years (n = 274) and ≥ 65 years (n = 293) and summarized by treatment arm for the safety population. In general, the incidences of the TEAEs were similar between the two age subgroups. For the more commonly occurring AEs in the two treatment arms, notable (≥ 10 percentage points) differences observed between the two age subgroups (< 65 and ≥ 65 years, respectively), with the higher incidence in the older ≥ 65 years subgroup, were as follows: anemia (37.2% and 52.7% in the R2-CHOP arm; 29.9% and 40.8% in placebo/R-CHOP arm), febrile neutropenia (8.8% and 18.5% in R2-CHOP), constipation (27.0% and 37.7% in R2-CHOP), diarrhea (13.1% and 23.3% in R2-CHOP; 9.5% and 19.7% in placebo/R-CHOP), and peripheral edema (5.1% and 18.5% in R2-CHOP).
Previously Untreated, Stage II-IV, CD20+ DLBCL

Select by GEP NanoString

Stratification by
IPI score (≥ 3)
Bulky disease (< 7 ≥ 7 cm)
Age (< 65 ≥ 65 y)

R2-CHOP (n = 285)
Lenalidomide PO 15 mg, d1-14 + R-CHOP
21-day cycles x6 cycles

Placebo/R-CHOP (n = 285)
Placebo PO d1-14 + R-CHOP
21-day cycles x6 cycles

Required neutropenia prophylaxis per local practice with G-CSF/GM-CSF

FIG A1. ROBUST study design (ClinicalTrials.gov identifier: NCT02285062; EudraCT 2013-004054-21). Following confirmation of CD20 positivity and identification of ABC-type by gene expression profiling, patients were stratified by IPI score, bulky disease, and age, and randomly assigned 1:1 to R2-CHOP or placebo/R-CHOP. Patients with non–ABC-type DLBCL were ineligible for the study. Treatment included the following: lenalidomide (or placebo) 15 mg oral (PO) on days 1-14 of every 21-day dosing cycle plus R-CHOP21 (rituximab 375 mg/m² intravenous [IV] day 1 or 1, cyclophosphamide 750 mg/m² IV day 1, doxorubicin 50 mg/m² IV day 1, vincristine 1.4 mg/m² [maximum 2.0 mg total] IV day 1, and prednisone [or prednisolone] 100 mg PO days 1-5 [IV day 1 was acceptable]). Treatment was continued until six cycles were complete, or until intolerability, inadequate response, disease progression, or withdrawal of consent, whichever occurred first. Two additional doses of single-agent rituximab (one dose per 21-day cycle) were permitted if prespecified and considered standard of care per local practice. ABC, activated B-cell-like; DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index; IV, intravenous; PO, oral; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.

FIG A2. Overall survival based on treatment group and age < 60 years (A) and ≥ 60 years (B) (ITT population). R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.
| Principal Investigator                  | Site Location                                                                 |
|----------------------------------------|-------------------------------------------------------------------------------|
| Uri Abadi                              | Meir Medical Center, Kfar Saba, Israel                                        |
| Yasunobu Abe                           | National Hospital Organization Kyushu Cancer Center, Fukuoka-city, Fukuoka, Japan |
| David Aboulafia                        | Virginia Mason Medical Center, Seattle, WA                                     |
| Pau Abrisqueta                         | Hospital Universitari Vall d’Hebron, Barcelona, Spain                         |
| Abdulwahab Al Tourah                  | British Columbia Cancer Agency—Fraser Valley Centre, Surrey, British Columbia, Canada |
| Sergey Alekseev                       | FSBI “Research Oncology Institution n.a. N.N. Petrov” of the RF MoH, Saint Petersburg, Russia |
| Alvaro Alencar                        | Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL         |
| Achille Ambrosetti                    | AOU Integrata di Verona-Universita di Verona-Policlinico G.B. Rossi, Verona, Italy |
| Daniel Anderson                       | HealthPartners Riverside Clinic, Minneapolis, MN                             |
| Kyoshi Ando                           | Tokai University Hospital, Isehara, Kanagawa, Japan                           |
| Marc André                            | Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Belgium                  |
| Francesco Angrilli                    | Ospedale Civile Santo Spirito di Pescara, Pescara, Italy                      |
| Luca Arcaini                          | Fondazione IRCCS Policlinico San Matteo, Pavia, Italy                         |
| Reyes Arranz                          | Hospital Universitario de La Princesa, Madrid, Spain                          |
| Irit Avivi                            | Tel Aviv Sourasky Medical Center, Tel Aviv, Israel                            |
| Giuseppe Avvisati                     | Policlinico Universitario Campus Bio-Medico, Rome, Italy                     |
| Orhan Ayyildiz                        | Dicle University Faculty Of Medicine Hospital, Internal Disease Hematology Department, Diyarbakir, Turkey |
| Johanna Baars                         | NKI-AVL, Amsterdam, the Netherlands                                          |
| Veronika Bachanova                    | University of Minnesota Medical Center, Minneapolis, MN                        |
| Christopher L. Bacon                  | St James’s Hospital, Dublin Ireland                                           |
| Monica Balzarotti                     | Istituto Clinico Humanitas, Rozzano, Italy                                   |
| Anne Banos                            | Ce H de La Côte Basque, Bayonne, France                                      |
| J. Bargay Leonart                     | Hospital Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain                |
| Roberta Battistini                    | Azienda Ospedaliera San Camillo Fortanini, Roma, Italy                       |
| Anne Beaver                           | Duke Cancer Institute, Durham, NC                                            |
| Joseph T. Beck                        | Highlands Oncology Group, Rogers, AR                                         |
| Aart Beeker                           | Spaarne-Gasthuis, Hoofddorp, the Netherlands                                  |
| David Belada                          | Fourth Department of Internal Medicine-Hematology, Charles University Hospital and Faculty of Medicine, Hradec Královice, Czech Republic |
| Jose L. Bello Lopez                   | Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain |
| Neil Belman                           | St Luke’s University Health Network, Bethlehem, PA                            |
| Dina Ben-Yehuda                       | Hadassah Medical Organization, Ein Kerem, Jerusalem, Israel                   |
| Isabelle Bence-Bruckler               | Pharmacy Department, Ottawa Hospital, Ottawa, Ontario, Canada                 |
| Juan Miguel Bergua Burgués            | Servicio de Hematología, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain |
| Alberto Bessudo                       | California Cancer Associates for Research and Excellence Inc, Encinitas, CA    |
| Fontanet Bijou                        | Institut Bergonié, Bordeaux, France                                          |
| Ian Bilmon                            | Westmead Hospital, Westmead, New South Wales, Australia                      |
| Robert Blum                           | Bendigo Health, The Bendigo Hospital Campus, Medical Oncology Unit, Bendigo, Victoria, Australia |
| Sabela Bobillo                        | Hospital Universitari Vall d’Hebron, Barcelona, Spain                       |
| Ralph Boccia                          | Center for Cancer and Blood Disorders, Bethesda, MD                          |
| Rinske Boersma                        | Amphia Ziekenhuis, Breda, the Netherlands                                   |
| Lara H. Böhmer                        | Haga Ziekenhuis, Den Haag, the Netherlands                                   |

(continued on following page)
| Principal Investigator               | Site Location                                                                 |
|-------------------------------------|-------------------------------------------------------------------------------|
| Serge Bologna                       | CHU de Nancy-Hôpitaux de Brabois, Vandoeuvre-lès-Nancy, France                 |
| Christophe Bonnet                   | CHU de Liège—Sart Tilman, Domaine Universitaires du Sart Tilman B35, Liège, Belgium |
| Alberto Bosi                        | Azienda Ospedaliera Universitaria Careggi, Firenze, Italy                     |
| Kamal-Krimo Bouabdallah             | University Hospital Haut-Lévêque, Pessac, France                              |
| Javier M. Briones                   | Hospital de la Santa Creu i Sant Pau, Barcelona, Spain                        |
| Fernando Cabanillas                 | Hospital Española Auxilio Mutuo de Puerto Rico, Inc, Farmacia Clinica Auxilio Mutuo, Hato Rey, Puerto Rico |
| Catello Califano                    | P.O. “Andrea Tortora” di Pagani, Pagani, Salerno, Italy                       |
| Philip Campbell                     | Geelong Hospital, Geelong, Victoria, Australia                                |
| Miguel A. Canales Albendea          | Hospital Universitario La Paz, Madrid, Spain                                  |
| Angelo M. Carella                   | IRCCS Az. Osp. Universitaria San Martino—IST, Genova, Italy                   |
| Guillaume Cartron                   | Hôpital Saint-Eloi, Montpellier, France                                      |
| Kimberly Cartwright                 | Wollongong Hospital, Wollongong, New South Wales, Australia                   |
| Susana M. C. Carvalho               | Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal |
| Michael Castine III                 | Hematology/Oncology Clinic LLP, Baton Rouge, LA                              |
| Januario Castro                     | UC San Diego Moores Cancer Center, La Jolla, CA                               |
| John Catalan                        | Peninsula Health, Frankston Hospital, Frankston, Victoria, Australia          |
| Federica Cavallo                    | AOU Città della salute e della Scienza di Torino, Turin, Italy                |
| Martine E. D Chamuteau              | VU Medisch Centrum, Amsterdam, the Netherlands                               |
| Arvind Chaudhry                     | Medical Oncology Associates, PS, Spokane, WA                                  |
| Chih-Cheng Chen                     | Chang Gung Medical Foundation Chiayi Chang Gung Memorial Hospital, Pu-zi City, Chiayi County, Taiwan |
| Annalisa Chiappella                 | AOU Città della Salute e della Scienza di Torino, Turin, Piemonte, Italy      |
| Seok-Goo Cho                        | The Catholic University of Korea, Seoul St Mary's Hospital, Seoul, Republic of Korea |
| Yuvraj Choudhary                    | Virginia Cancer Institute, Richmond, VA                                       |
| Angela G. Congiu                    | Azienda Ospedaliera Universitaria San Martino, Genova, Italy                  |
| Paolo Corradini                     | Fondazione IRCSS INT, Milano, Italy                                          |
| John Crown                          | St Vincent's University Hospital, Dublin, Ireland                             |
| Michael Crump                       | Princess Margaret Cancer Centre, Toronto, Ontario, Canada                     |
| Juan Cuevas                         | St Louis Cancer Care LLP, Bridgeton, MO                                       |
| Ricardo J. S. M. da Costa           | Hospital Garcia de Orta, E.P.E, Almada, Portugal                             |
| Nicolas Daguindau                   | C H Annecy Genevois, Pringy Cedex, France                                    |
| Ivona Danielewicz                   | Szpital Wojewódzkie w Gdyni Sp, z o. o., Gdyński Centrum Onkologii Oddział Chemioterapii, Gdynia, Poland |
| Dries Deeren                        | AZ Delta, Roeselare, West-Vlaanderen, Belgium                                 |
| Luis de la Cruz Merino              | Hospital Universitario Virgen Macarena, Sevilla, Spain                        |
| Richard Delarue                     | Hôpital Necker, Paris, France                                                 |
| Muzaffer Demir                      | Trkya Universitesi Tip Fakultesi Hastanesi, Balkan Yerleþkesi,Hematoloji Bilim Dali, Edirne, Turkey |
| Hilde Demuynck                      | Regionaal Ziekenhuis Jan Yperman VZW, Leper, Belgium                          |
| Pierre Desjardins                   | Centre de Santé et de Services Sociaux Champlain Charles LeMoyne, Greenfield Park, Quebec, Canada |
| Francesco Di Raimondo               | Presidio “Ferrartaro Alessi”, Azienda Ospedaliero-Universitaria Policlinico Vittorio Emanuele, Catania, Italy |
| Andrei M. Dobrescu                  | Regional Cancer Care Associates LLC - Somerville, Somerville, NJ              |

(continued on following page)
| Principal Investigator | Site Location |
|------------------------|---------------|
| Toshihiko Doi          | National Cancer Center Hospital East, Kashiwa, Chiba, Japan |
| Sean Dolan             | Saint John Regional Hospital, Saint John, New Brunswick, Canada |
| Eva Ma Donato Martin   | Hospital Universitario Doctor Peset, Valencia, Spain |
| Xin Du                 | Guangdong General Hospital, Guangzhou, Guangdong, China |
| Nazik Durdu-Rayman     | Vietland Ziekenhuis, Schiedam, the Netherlands |
| Marc Durian            | Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands |
| Richard Eek            | Border Medical Oncology, Wodonga, Victoria, Australia |
| Hyeon Seok Eom         | National Cancer Center, Gyeonggi-do, Republic of Korea |
| Bulent Eser            | Erçiyes University Faculty of Medicine Mehmet Kemal Dedeman, Hematology Oncology Hospital, Kayseri Melikgazi, Turkey |
| Alberto Fabbri         | Azienda Ospedaliera Universitaria Senese, Siena, Italy |
| Charles Farber         | Regional Cancer Care Associates LLC—Morristown, Carol G. Simon Cancer Center, Morristown, NJ |
| Pier P. Fattori        | IRCSS I.R.S.T, Meldola, Italy |
| Ji-Feng Feng           | Jiangsu Cancer Hospital, Nanjing, Jiangsu, China |
| Ru Feng                | Nanfang Hospital of Southern Medicine University, Guangzhou, Guangdong, China |
| Burhan Ferhanoglu      | American Hospital Hematology Department, Istanbul, Turkey |
| Eugenio Fernandez      | Centre d ‘Oncologie, Hôpitaux Universitaire de Genève-Rue, Genève, Suisse, Switzerland |
| Andrés J. M. Ferreri   | IRCCS Ospedale S. Raffaele, Milano, Italy |
| Pierre Feugier         | CHU de Nancy-Hôpitaux de Brabois, Vandoeuvre-lès-Nancy, France |
| Natalie Fischer        | Kantonsspital Winterthur- Medizinische Onkologie, Winterthur, Switzerland |
| RobinFilshie           | St Vincent’s Hospital, Melbourne, Victoria, Australia |
| Scott Fleischauer      | Texas Oncology Arlington North, Arlington, TX |
| Patricia Font Lopez    | Hospital General Universitario Gregorio Marañón, Madrid, Spain |
| Anne Fortune           | Mater Misericordiae University Hospital, Dublin, Ireland and Mater Private Hospital, Dublin, Ireland |
| Roberto Freilone       | Ospedale di Ivrea, Ivrea, Torino, Italy |
| Carl Freter            | Saint Louis University Cancer Center, St Louis, MO |
| Hiroshi Fujiwara       | Ehime University Hospital, Shitsukawa, Toon, Ehime, Japan |
| Yousuf Gaffar          | University of Maryland St Joseph Medical Center Cancer Institute, Townson, MD |
| Gianluca Gaidano       | Azienda Ospedaliera Universitaria “Maggiore della Carità”, Novara, Italy |
| Peter Ganly            | Canterbury Health Laboratories, Christchurch, Canterbury, New Zealand |
| Gregory Gareth         | Monash Health, Monash Medical Centre, Clayton, Victoria, Australia |
| Randy D. Gascoyne      | Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada |
| Anupkumar George       | Capital and Coast District Health Board, Wellington Hospital, Newtown, Wellington, North Island, New Zealand |
| Guido Gini             | AOU Ospedali Riuniti di Ancona, Torettto di Ancona, Ancona, Italy |
| Manilha Gomes          | Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal |
| Maria Gomes da Silva   | Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal |
| José Gomez Codina      | Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain |
| Cristina M. A. P. Gonçalves | Centro Hospitalar do Porto EPE - Hospital de Santo António, Porto, Portugal |
| Andre Goy              | John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ |
| Carlos Grande Garcia   | Hospital Universitario 12 de Octubre, Madrid, Spain |
| Cliona Grant           | St James’s Hospital, Dublin Ireland |
| Mariella Grasso        | Azienda Sanitaria Ospedaliera “S. Croce e Carle,” Cuneo, Italy |
| Richard H. Greenberg   | Regional Cancer Care Associates LLC-Cherry Hill, Cherry Hill, NJ |

(continued on following page)
TABLE A1. List of ROBUST Study Investigators (continued)

| Principal Investigator   | Site Location                                                                 |
|--------------------------|-------------------------------------------------------------------------------|
| Andrew Grigg             | Austin Health-Hospital, Heidelberg, Victoria, Australia                       |
| Fátima Guedes            | Hospital Distrital da Figueira da Foz EPE, Figueira da Foz, Portugal          |
| Ronit Gurion             | Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel                  |
| Birol Guvenc             | Cukurova University Faculty of Medicine, Internal Diseases Hematology Department, Adana, Balcali, Turkey |
| Sibel K. Hacioglu        | Pamukkale University Faculty of Medicine Hospital, Department of Hematology, Denizli, Kinikli, Turkey |
| Corinne Haioun           | Hôpital Henri Mondor, Créteil, France                                        |
| Janusz Halka             | Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewntrznycznych z Warminsko- Mazurskim Centrum Onkoligii, Oddzial Hematologii, Olszyn, Poland |
| Kiyohiko Hatake          | The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-ku, Tokyo, Japan |
| Timothy Hawkins          | Auckland DHB, Auckland City Hospital, Auckland, Auckland Region, New Zealand |
| Amjad Hayat              | University Hospital Galway, Galway, Ireland                                   |
| José A. Hernández Rivas  | Hospital Universitario Infanta Leonor, Madrid, Spain                          |
| Eduardo R. Herranz       | Hospital Universitario de Valme, Sevilla, Spain                              |
| Xiaonan Hong             | Fudan University Shanghai Cancer Center, Shanghai, China                      |
| Netanel Avraham Horowitz | Rambam Health Care Campus, Haifa, Israel                                     |
| Robert Hoyer             | Memorial Hospital, Colorado Springs, CO                                      |
| Jianda Hu                | Fujian Medical University Union Hospital, Fuzhou, Fujian, China              |
| Huqiang Huang            | Sun Yatzen University Cancer Center, Guangzhou Guangdong, China              |
| Takayuki Ikezoe          | Kochi Medical School Hospital, Oko-cho, Nankoku-shi, Kochi, Japan            |
| Kenichi Ishizawa         | Yamagata University Hospital, Ida-Nishi, Yamagata, Yamagata, Japan           |
| Iris Isufi               | Smilow Cancer Hospital at Yale-New Haven, New Haven, CT                       |
| Koji Izutsu              | National Cancer Center Hospital, Tokyo, Japan                                 |
| Deepa Jeyakumar          | UC Irvine Medical Center, Chao Family Comprehensive Cancer Center, Orange, CA |
| Jie Jin                  | The First Affiliated Hospital of Medical School of Zhejiang University, First Hospital of Zhejiang Province, Hangzhou, Zhejiang, China |
| Zhengming Jin            | The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China   |
| Wojciech Jurczak         | Jagiellonian University, Kraków, Poland                                      |
| Yoshihiro Kameoka        | Akita University Hospital, Hiroomote, Akita-shi, Akita, Japan                |
| Zevad Kanaan             | UT/Memorial Hermann Cancer Center, Houston, TX                                |
| Barry Kaplan             | Queens Medical Associates PC, Fresh Meadows, NY                              |
| Kasra Karmalou           | John Muir Medical Centre, Concord, CA                                        |
| Koji Kato                | Kyushu University Faculty of Medicine, Fukuoku-City, Japan                   |
| Xiaoyan Ke               | Peking University Third Hospital, Haidian District, Beijing, China            |
| Stephan D. Kendall       | Utah Cancer Specialists, Salt Lake City, UT                                  |
| Robert M. Kessler        | Cancer Center at West Jefferson Medical Center New Orleans Physicians Services, Inc, Marrero, LA |
| Nadia Khan               | Fox Chase Cancer Center, Philadelphia, PA                                    |
| Toru Kiguchi             | Japan Mutual Aid Association of Public School Teachers Chugoku Central Hospital, Kamiwanari, Miyuki-cho, Fukuyama, Hiroshima, Japan |
| Allanah Kilfoyle         | MidCentral DHB, Palmerston North Hospital, Palmerston North, Manawatu- Wanganui, New Zealand |
| Saadettin Kilkip         | Hacettepe Universitesi Tip Fakultesi Onkoloji Hastanesi, Preventif Onkoloji Anabilim Dali, Sihhiye, Ankara, Turkey |
| Jin-Seok Kim             | Severance Hospital Yonsei University Health System, Seoul, Republic of Korea |
| Won Seog Kim             | Samsung Medical Center, Seoul, Republic of Korea                             |

(continued on following page)
| Principal Investigator                        | Site Location                                                                                           |
|----------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Wanda Knopinska-Poslusny                      | Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych z Warminsko-Mazurskim Centrum Onkологии, Oddzial Hematologii, Olsztyn, Poland |
| Tsutomu Kobayashi                             | University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Kyoto, Japan                  |
| Maya Koren-Michowitz                          | Assaf Harofeh Medical Center, Beer Yaakov, Zerifin, Israel                                            |
| Mauro Krampera                                | AOI Integrata di Verona- Universita di Verona-Policlinico G.B. Rossi, Verona, Italy                    |
| Kazimierz Kuliczkowski                        | Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Klinika Hematologii Nowotworow Krwi i Transplantacji Szpiku, Wroclaw, Poland |
| Charles S. Kuzma                              | FirstHealth Outpatient Cancer Center, Pinehurst, NC                                                   |
| Alexey Kuzmin                                 | SAHI (Republican Clinical Oncology Dispensary Ministry of Healthcare of the Tatarstan Republic), Kazan, Russia |
| Thierry Lamy De La Chapelle                   | CHRU Rennes-Hôpital Pontchaillou, Rennes Cedex 9, France                                             |
| Vincent Launay                                | CH Yves le Foll, Saint Brieuc, France                                                                 |
| Aleksandr Lazaryan                            | University of Minnesota Medical Center, Minneapolis, MN                                               |
| Steven Le Gouill                              | CHU Hôtel Dieu, Nantes Cedex, France                                                                  |
| Maria B. L. Leis                              | Maasstad Ziekenhuis, Rotterdam, the Netherlands                                                       |
| Jan Lemmens                                   | GZA St Augustinus, Wilrijk, Belgium                                                                  |
| Itai Levi                                    | Soroka University Medical Centre, Beer-Sheva, Israel                                                  |
| Lawrence Lewkow                               | Virginia Cancer Institute, Richmond, VA                                                                |
| Wei Li                                        | First Hospital of Jilin University, Changchun, Jilin, China                                           |
| Anna M. Liberati                              | AOS Maria Di Terni, Terni, Italy                                                                     |
| Jiazhuo Liu                                   | West China Hospital of Sichuan University, Chengdu, Sichuan, China                                    |
| Armando G. López                              | Hospital Clinic, Barcelona, Spain                                                                    |
| Javier Lopez                                 | Hospital Universitario Ramón y Cajal, Madrid, Spain                                                   |
| Paulo Lúcio                                   | Fundação Champalimau, Lisboa, Portugal                                                                |
| Stefano Luminari                              | Azienda Ospedaliero—Universitaria Policlinico di Modena, Modena, Italy                               |
| Hongbin Ma                                   | West China Hospital of Sichuan University, Chengdu, Sichuan, China                                    |
| Viguria A. Ma Cruz                            | Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain                                           |
| Hervé Maisonneuve                             | CHD Vendée, Hôpital de la Roche-sur-Yon, La Roche-sur-Yon Cedex 9, France                            |
| Ignazio Majolino                              | Azienda Ospedaliera San Camillo Forlanini, Roma, Italy                                               |
| Salman Malad                                  | Cancer Center of Acadiaana—Lafayette General Medical Center, Lafayette, LA                           |
| Christoph Mamof                               | Kantonsklinik Aarau AG—Zentrum für Onkologie, Hämatologie und Tranfusionsmedizin, Tellstrasse, Aarau, Switzerland |
| Maurizio Martelli                             | Azienda Policlinico Umberto I, Roma, Italy                                                           |
| Alejandro Martin Garcia-Sancho                | Hospital Universitario de Salamanca, Salamanca, Spain                                                |
| Jiří Mayer                                   | Fakultní Nemocnice Brno, Interni Hematologická a Onkologická Klinika, Brno, Czech Republic          |
| Matthew McKinney                              | Duke Cancer Institute, Durham, NC                                                                    |
| Francesco Merli                              | AO Acrispedale di Reggio Emilia Santa Maria Nuova/rcss, Reggio Emilia, Italy                         |
| Martha Mims                                   | Baylor College of Medicine, Houston, TX                                                               |
| Yosuke Minami                                | National Cancer Center Hospital East, Kashiwa, Chiba, Japan                                           |
| Monique C. Minnema                            | UMC Utrecht, Utrecht, the Netherlands                                                                |
| Heidi Mocikova                                | Faculty Hospital Kralovskie Vinohrady, Prague, Czech Republic                                        |
| Anna L. Molinari                              | Ospedale Degli Infermi, Rimini, Italy                                                                |
| Luigina Mollica                              | Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada                                               |
| Michael R. Moore                              | Willis-Knighton Cancer Center, Shreveport, LA                                                        |
| Masakazu Mori                                | Kochi Medical School Hospital, Oko-cho, Nankoku-shi, Kochi, Japan                                    |

(continued on following page)
| Principal Investigator                     | Site Location                                                                 |
|-------------------------------------------|-------------------------------------------------------------------------------|
| Gerardo Musuraca                          | IRCSS I.R.S.T., Meldola, Italy                                                |
| Pellegrino Musto                          | IRCSS Centro Di Riferimento Oncologico della Basilicata, Rionero in Vulture, Potenza, Italy |
| Arnon Nagler                              | Chaim Sheba MC, Tel-Hashomer, Ramat-Gan, Israel                               |
| Neil Nagovsky                             | Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL         |
| Mohit Narang                              | Maryland Oncology Hematology, P.A., Columbia, MD                              |
| Robert Nickelson                          | Willis-Knighton Cancer Center, Shreveport, LA                                  |
| Concepción G. Nicolás                    | Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain           |
| Grzegorz Nowakowski                       | Mayo Clinic, Rochester, MN                                                    |
| Lucie Oberic                              | Institut Universite du Cancer, Toulouse, France                                |
| Isabel Oliveira                           | Instituto Portugues de Oncologia do Porto Francisco Gentil EPE, Porto, Portugal |
| Annibali Ombretta                         | Policlinico Universitario Campus Bio-Medico, Rome, Italy                      |
| Stephen Opat                              | Monash Health, Monash Medical Centre, Clayton, Victoria, Australia             |
| Derville O’Shea                           | Health Service Executive, Cork University Hospital, Cork, Ireland              |
| Dzhelil Osmanov                           | FSBI “Russian Oncology Research Center n.a. Blokhn“ of Ministry of Healthcare of RF, Moscow, Russia |
| Lindsay Overton                           | Wenatchee Valley Hospital and Clinics, Wenatchee, WA                          |
| Caryolyn Owen                             | Tom Baker Cancer Centre, Calgary, Alberta, Canada                              |
| Muhit ¨Ozcan                              | Ankara University, Ankara, Turkey                                             |
| Guner H. Oztan                            | Dokuz Eylul University Faculty of Medicine Hematology Department, Izmir, Balcova, Turkey |
| John Pagel                                | Swedish Cancer Institute, Seattle, WA                                         |
| Tomáš Papaj                               | Fakultni Nemocnice Olomouc, Hemato-Onkologická Klinika, Olomouc, Czech Republic |
| Fabrizio Pane                             | AOI Federico II, Via Sergio Pansini, Napoli, Italy                            |
| Carlos Panizo Santos                      | Clinica Universidad de Navarra, Pamplona, Navarra, Spain                       |
| Guido Parvis                              | AOI San Luigi Gonzaga, Orbassano, Torino, Italy                               |
| Vincenzo Pavone                           | Azienda Ospedaliera Cardinale G Panico Pia Fondazione di Culto e Religione, Tricase(LE), Italy |
| David Peace                               | University of Illinois Cancer Center, Chicago, IL                              |
| Jaime Pérez de Oteyza                    | Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain                |
| Ma Angeles Pérez Saenz                    | Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain                  |
| Francesco Piazza                         | University of Padova and Azienda Ospedaliera di Padova, Padova, Italy         |
| Antonio Pinto                             | IRCICS Istituto Naz Studio e Cura Tumori—“Fond G. Pascale”, Napoli, Italy     |
| Andrew W. Pippas                          | John B. Amos Cancer Center, Columbus, GA                                     |
| Samantha Pozzi                           | Azienda Ospedaliera—Universitaria Policlinico di Modena, Modena, Italy        |
| Vishnu Prakash                           | Virginia Mason Medical Center, Seattle, WA                                     |
| Elena Prieto                              | Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain                  |
| Vít Procházka                             | Fakultni Nemocnice Olomouc, Hemato-Onkologická Klinika, Olomouc, Czech Republic |
| Debra Prow                                | McFarland Clinic P.C., Ames, IA                                               |
| Hans Pruitt                               | Jeroen Bosch Ziekenhuis, Hertogenbosch, the Netherlands                      |
| Radhakrishnan Ramchandren                | Karmanos Cancer Institute, Detroit, MI                                        |
| Brian Randolph                           | Southeastern Regional Medical Center, Newnan, GA                               |
| Christopher M. Reynolds                  | St Joseph Mercy Hospital, Cancer Care Center, Ann Arbor, MI                   |
| Vincent Ribrag                            | Institut Gustave Roussy, Villejuif, France                                    |
| Adam Rios                                 | UT/Memorial Hermann Cancer Center, Houston, TX                                |
| Syed Rizvi                                | UT Southwestern Medical Center, Dallas, TX                                    |
| Guillermo Rodriguez Garcia               | Hospital Universitario Virgen del Rocio, Sevilla, Spain                       |

(continued on following page)
| Principal Investigator | Site Location |
|------------------------|---------------|
| Maria J. Rodríguez-Salazar | Hospital Universitario de Canarias, Canarias, Spain |
| Giuseppe Rossi | Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy |
| Rosa Ruchlemmer | Shaare Zedek Medical Center, Jerusalem, Israel |
| Antonio Rueda Dominguez | Hospital Costa del Sol, Marbella, Málaga, Spain |
| Marco Ruiz | Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, FL |
| Chiara Rusconi | Azienda Ospedaliera Ospedale Niguarda Ca’Granda, Milan, Italy |
| Piotr Rzepecki | Wojskowy Instytut Medyczny, Klinice Chorob Wewnętrznych i Hematologii, Warszawa, Poland |
| Rustem Safin | SAHI (Republican Clinical Oncology Dispensary Ministry of Healthcare of the Tatarstan Republic), Kazan, Russia |
| Muhammad Salim | Allan Blair Cancer Centre, Regina, Saskatchewan, Canada |
| Antonio Salar Silvestre | Hospital del Mar, Barcelona, Spain |
| Juan M. Sancho | Hospital Universitario Germans Trias i Pujol, Barcelona, Spain |
| Flavia Salvi | Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo Alessandria, Alessandria, Italy |
| Hakan I. Sari | Pamukkale University Faculty of Medicine Hospital, Department of Hematology, Denizli, Kinikli, Turkey |
| Ahmed Sawas | Columbia University Medical Center Herbert Irving Pavilion, New York, NY |
| Maria J. Sayas Lloris | Hospital Universitario Doctor Peset, Valencia, Spain |
| David W. Scott | Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada |
| Ofer Shpilberg | Assuta Medical Center, Hematology Division & Clinical Trials Division, Tel Aviv, Israel |
| Robert Siegel | Saint Francis Hospital Cancer Centre, Greenville, SC |
| Giorgina Specchia | Azienda Ospedale Unicersitaria Consorziale Policlinico di Bari, Bari, Italy |
| Michele Spina | Centro Di Riferimento Oncologico IRCSS, Aviano (PN), Italy |
| Anastasios Stathis | Ospedale San Giovanni, Via Ospedale, Bellinzona, Switzerland, Switzerland |
| Piero M. Stefani | Azienda ULSS n.9 Ospedale Ca’Foncello, Treviso, Italy |
| Caterina Stelitano | Grande Ospedale “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy |
| Lesley Street | Tom Baker Cancer Centre, Calgary, Alberta, Canada |
| Youko Suehiro | National Hospital Organization Kyushu Cancer Center, Fukuoka-city, Fukuoka, Japan |
| Cheolwon Suh | Asan Medical Center, Seoul, Republic of Korea |
| Jeffrey Szer | Royal Melbourne Hospital, Parkville, Victoria, Australia |
| Agostino Tafuri | Azienda Ospedaliera Universitari, Roma, Italy |
| Monica Tani | U.O. Ematologia, Dipartimento Oncologia e Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy |
| Masafumi Taniwaki | University Hospital, Kyoto Prefectural University of Medicine, Kyoto-city, Kyoto, Japan |
| Adrian Tempescul | CHU Brest - Hôpital Morvan, Brest Cedex, France |
| Maria J. Terol Castera | Hospital Clínico Universitario de Valencia, Valencia, Spain |
| Yasuhiro Terui | The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Koto-ku, Tokyo, Japan |
| Catherine Thébault | Hôpital Saint Louis, Paris, France |
| Maria C. Tisi | Azienda ULSS B “Berica”—Ospedale S. Bortolo, Vicenza, Italy |
| Marek Trněný | Všeobecná Fakultní Nemocnice v Praze, I. Interní Klinika—Klinika Hematologie, Prague, Czech Republic |
| Kunihiro Tsukasaki | National Cancer Center Hospital East, Kashiwa, Chiba, Japan |
| Anil Tulpule | USC/Norris Comprehensive Cancer Center, Los Angeles, CA |
| Gayane Tumyan | FSBI “Russian Oncology Research Center n.a. Blokhin” of Ministry of Healthcare of RF, Moscow, Russia |
| Joseph Tuscano | University of California Davis Comprehensive Cancer Center, Sacramento, CA |

(continued on following page)
| Principal Investigator | Site Location |
|------------------------|---------------|
| Levent Undar Akdeniz | Akdeniz University Tip Fakultesi Hastanesi ic Hastaliklari anabilim Dali, Hematoloji Bilim Dali, Dumlupinar Bulvari, Arapsuyu, Konyaalti, Antalya, Turkey |
| Isabelle Vande Broek | AZ Nikolaas, Sint-Niklaas, Oost-Vlaanderen, Belgium |
| Eric Van Den Neste | Cliniques Universitaires Saint-Luc, Brussels, Belgium |
| Rozemarijn Stephanie van Rijn | Medisch Centrum Leeuwarden, Leeuwarden, the Netherlands |
| Fernanda Vargas | Hospital Garcia de Orta, E.P.E, Almada, Portugal |
| Carlo Visco | Azienda ULSS 8 “Berica”—Ospedale S. Bortolo, Vicenza, Italy |
| Umberto Vitolo | AOU Città della Salute e della Scienza di Torino, Turin, Piemonte, Italy |
| Stefano Volpetti | Azienda Ospedaliero Universitaria S.Maria Della Misericordia di Udine, Udine, Italy |
| Madhuri Vusrikala | UT/Memorial Hermann Cancer Center, Houston, TX |
| Patricia Walker | Peninsula Health, Frankston Hospital, Frankston, Victoria, Australia |
| John Wallmark | Maryland Oncology Hematology PA, Rockville, MD |
| Ming-Chung Wang | Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital, Niao-sung District, Kaoshiung, Taiwan |
| Po-Nan Wang | Chang Gung Medical Foundation, Linkou Branch, Taoyuan, Taiwan |
| Donald Wender | Siouxsland Regional Cancer Center dba June E. Nylen Cancer Center, Sioux City, IA |
| Thomas E. Witzig | Mayo Clinic, Rochester, MN |
| Tomasz Wozny | SPZOZ MSW w Poznaniu im. Prof. Ludwika Bierkowskiego, Oddzial Hematologii, Poznan, Wielkopolskie, Poland |
| Tomasz Wrobel | Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Klinika Hematologii Nowotworow Krwi i Transplantacji Szpiku, Wroclaw, Poland |
| Wei Xu | Jiangsu Province Hospital, Nanjing, Jiangsu, China |
| Abdurraheem Yacoub | The University of Kansas Cancer Center and Medical Pavilion, Westwood, KS |
| Go Yamamoto | Toranomon Hospital, Minato-ku, Tokyo, Japan |
| Kazuhito Yamamoto | Aichi Cancer Center Hospital, Nagoya, Japan |
| Shenmiao Yang | Peking University People’s Hospital, Xicheng District, Beijing, China |
| Ming Yao | National Taiwan University Hospital, Taipei City, Taiwan |
| Victor Yazbeck | Virginia Commonwealth University Massey Cancer Center, Dalton Oncology Clinic, Richmond, VA |
| Su-Peng Yeh | China Medical University Hospital, Taichung City, Taiwan |
| Charles Yen | Millennium Oncology, Houston, TX |
| Mustafa N. Yenerel | Istanbul Universitesi Istanbul Tip Fakultesi, Ic Hastaliklari Anabilim Dali, Hematoloji Bilim Dali, Fatih, Capa, Istanbul, Turkey |
| Hisayuki Yokoyama | National Hospital Organization Sendai Medical Center, Sendai-City, Miyagi, Japan |
| Dok Hyun Yoon | Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea |
| Francesco Zaja | Azienda Ospedaliero Universitaria S.Maria Della Misericordia di Udine, Udine, Italy |
| Francesco Zallio | Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Amigo Alessandria, Alessandria, Italy |
| Jan Zaucha | Szpital w Wojewódzkie w Gdyni Sp. z o. o., Gdymskie Centrum Onkologii Oddzial Chemioterapii, Gdynia, Poland |
| Huilai Zhang | Tianjin Medical University Cancer Institute & Hospital, Hexi District, Tianjin, China |
| Li Zhang | West China Hospital of Sichuan University, Chengdu, Sichuan, China |
| Qingyuan Zhang | Harbin Medical University Cancer Hospital, Nangang District, Harbin, Heilongjiang, China |
| Wei Zhang | Peking Union Medical College Hospital, Wangfujing, Dongcheng District, Beijing, China |
| Xi Zhang | The Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China |
| Jianfeng Zhou | Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China |
| Jun Zhu | Beijing Cancer Hospital, Haidian District, Beijing, China |
| Pier Luigi Zinzani | A.O.U Policlinico S. Orsola Malpighi, Bologna, Italy |
### TABLE A2. TEAEs (≥ 1%) Leading to Lenalidomide or Placebo Discontinuation

| TEAEs, No. (%)                  | R2-CHOP (n = 283) | Placebo/R-CHOP (n = 284) |
|---------------------------------|-------------------|--------------------------|
| Patients with at least 1 TEAE leading to lenalidomide or placebo discontinuation | 49 (17)           | 32 (11)                  |
| Neutropenia                     | 23 (8)            | 15 (5)                   |
| Thrombocytopenia                | 8 (3)             | 3 (1)                    |
| Febrile neutropenia             | 7 (2)             | 2 (1)                    |
| Leukopenia                      | 6 (2)             | 2 (1)                    |
| Pulmonary embolism              | 4 (1)             | 1 (< 1)                  |

Abbreviations: R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP; TEAE, treatment-emergent adverse event.

### TABLE A3. Causes of Death in the R2-CHOP and Placebo/R-CHOP Treatment Arms

| Causes of Death, No. (%)                  | R2-CHOP (n = 283) | Placebo/R-CHOP (n = 284) |
|-------------------------------------------|-------------------|--------------------------|
| Overall deaths                             | 57 (20)           | 62 (22)                  |
| Malignant disease or complications thereof | 49 (17)           | 44 (15)                  |
| Adverse event (not otherwise specified)   | 3 (1)             | 7 (2)                    |
| Unknown cause (not assessable or insufficient data) | 3 (1)             | 6 (2)                    |
| Second primary malignancy*                | 2 (1)             | 2 (1)                    |
| Death from other cause                    | 0                 | 3 (1)                    |

Abbreviations: R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.

*Second primary malignancies included 1 acute myeloid leukemia and 1 squamous cell carcinoma of the tongue the R2-CHOP arm, and 1 each lung and gastric adenocarcinomas in the placebo/R-CHOP arm.